• Skip to main content
BC

biochimica clinica

en_US English
en_US English it_IT Italian
  • Home
  • Casi clinici
  • Ahead of print e Ultimo Fascicolo - Accedi per visualizzare gli articoli
  • Archivio BC fino a 2024
  • Sottometti un articolo
  • Norme Autori
  • Cerca

CONTRIBUTI SCIENTIFICI – Scientific Papers

Volume:

Biochimica Clinica 2018; 42(3) 234-239

Pubblicato on-line:

May 25, 2018

DOI:

10.19186/BC_2018.034

Scarica in PDF:
Autenticazione richiesta

Glycated albumin is correlated to insulin resistance and β-cell secretory function in subjects at risk of developing diabetes

AUTORI

Chiara Bellia1, Martina Zaninotto3, Chiara Cosma3, Luisa Agnello1, Bruna Lo Sasso1, Patrizia Altavilla2, Giulia Bivona1, Giuseppe Pizzolanti2, Sergio Bernardini4, Mario Plebani3*, Marcello Ciaccio1,2*
1Department of Biopathology and Medical Biotechnologies, Section of Clinical Biochemistry and Clinical Molecular Medicine, University of Palermo
2Department of Laboratory Medicine, University Hospital, Palermo
3Department of Laboratory Medicine, University Hospital, Padua
4Department of Experimental Medicine and Surgery, Division of Clinical Biochemistry, University of Rome Tor Vergata, Rome
*Mario Plebani and Marcello Ciaccio are both considered last Authors

ABSTRACT

Insulin resistance and β-cell secretory function represent two main issues in the pathogenesis of type 2 diabetes mellitus (T2DM). Conflicting results have been obtained about the association between glycated albumin (GA) and body mass index (BMI), insulin resistance and β-cell function in diabetic patients. Actually, the relationship (if any) between GA and the markers of glucose homeostasis and insulin resistance in subjects at risk of developing diabetes, has not been completely elucidated yet. Two hundred and one patients undergoing to oral glucose tolerance test (OGTT) were enrolled in the study. Routine laboratory tests, including fasting insulin, were performed at enrollment. GA was measured on plasma-EDTA by quantILab® Glycated Albumin (Instrumentation Laboratory, A Werfen Company) on ILab Taurus analyzer. According to the plasma glucose concentration measured after 2 hours of glucose intake (2h- PG), 13 subjects (6.4%) were classified as impaired glucose tolerance (IGT). GA weakly correlated with fasting plasma glucose (FPG) (r=0.21; P=0.002), with HbA1c (r=0.16; P=0.024) but not with 2h-PG (P=0.7). GA, but not HbA1c, was negatively correlated to HOmeostasis Model Assessment for β cell fuction (HOMA-β) (r2=0.23; P<0.001), to HOMA for insulin resistence (HOMA-IR) (r2=0.15; P<0.0001) and to BMI (r2=0.05; P=0.001). In a stepwise multivariate regression analysis including HbA1c, HOMA-β, plasma albumin, BMI, eGFR, age, FPG, and HOMA-IR as predictors of GA, only HbA1c (β-coefficient: 0.04; P=0.038) and HOMA-β (β-coefficient: -0.01; P<0.0001) were able to predict GA levels (r2=0.26; P<0.001 for the model). Our results demonstrated that GA was associated to HOMA-β and, to a lesser extent, to HOMA-IR and BMI. The increase of GA values can be explained by the reduction of β-cell secretory function in subjects with no significant increase of FPG and 2h-PG.

BIBLIOGRAFIA

HOME
PRIVACY POLICY
5x1000 Docemus

LOGO SIBioC

EDITORE RESPONSABILE
Alberto Oliaro

EDITORIAL SECRETARY
Edizioni Minerva Medica S.p.A.
Corso Bramante 83-85, 10126 Torino
T +39 011 678282
journals.dept@minervamedica.it

Designed by Biomedia srl
© 2025 SIBioC
P. IVA IT 06484860967